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Ganesan M, Zhang J, Bronich T, Poluektova LI, Donohue TM
Jr, Tuma DJ, Kharbanda KK, Osna NA. Acetaldehyde accelerates
HCV-induced impairment of innate immunity by suppressing meth-
ylation reactions in liver cells. Am J Physiol Gastrointest Liver
Physiol 309: G566–G577, 2015. First published August 6, 2015;
doi:10.1152/ajpgi.00183.2015.—Alcohol exposure worsens the
course and outcomes of hepatitis C virus (HCV) infection. Activation
of protective antiviral genes is induced by IFN- signaling, which is
altered in liver cells by either HCV or ethanol exposure. However, the
mechanisms of the combined effects of HCV and ethanol metabolism
in IFN- signaling modulation are not well elucidated. Here, we
explored a possibility that ethanol metabolism potentiates HCV-
mediated dysregulation of IFN- signaling in liver cells via impair-
ment of methylation reactions. HCV-infected Huh7.5 CYP2E1 cells
and human hepatocytes were exposed to acetaldehyde (Ach)-gener-
ating system (AGS) and stimulated with IFN- to activate IFN-
sensitive genes (ISG) via the Jak-STAT-1 pathway. We observed
significant suppression of signaling events by Ach. Ach exposure
decreased STAT-1 methylation via activation of protein phosphatase
2A and increased the protein inhibitor of activated STAT-1 (PIAS-
1)-STAT-1 complex formation in both HCV and HCV cells,
preventing ISG activation. Treatment with a promethylating agent,
betaine, attenuated all examined Ach-induced defects. Ethanol metab-
olism-induced changes in ISGs are methylation related and confirmed
by in vivo studies on HCV transgenic mice. HCV- and Ach-induced
impairment of IFN signaling temporarily increased HCV RNA levels
followed by apoptosis of heavily infected cells. We concluded that
Ach potentiates the suppressive effects of HCV on activation of ISGs
attributable to methylation-dependent dysregulation of IFN- signal-
ing. A temporary increase in HCV RNA sensitizes the liver cells to
Ach-induced apoptosis. Betaine reverses the inhibitory effects of Ach
on IFN signaling and thus can be used for treatment of HCV
alcohol-abusing patients.
ethanol metabolism; IFN- signaling; hepatitis C virus; hepatocytes;
betaine
WITH AN ESTIMATED 170 MILLION chronically infected persons,
hepatitis C virus (HCV) infection is the most common blood-
borne infection in the world. The prevalence of hepatitis C is 7-
to 10-fold higher in alcohol abusers than in the general popu-
lation (17), making the combination of HCV infection and
alcohol abuse a very common cause of chronic liver disease.
Alcohol consumption in patients infected with HCV exacer-
bates liver injury, leading to rapid progression to fibrosis,
cirrhosis, and even hepatocellular carcinoma (34). Alcohol
consumption significantly reduces responsiveness of patients
with HCV to antiviral treatment. The mechanism by which
alcohol consumption increases the severity of HCV infection is
unclear. In this regard, the possibility of synergistic effects of
HCV and alcohol on HCV spread and liver injury progression
cannot be excluded because hepatocytes are primary sites for
HCV replication and ethanol metabolism, both of which sup-
press innate immunity in liver cells.
Activation of an antiviral innate immune response is based
on IFN signaling. Type 1 IFNs per se possess no antiviral
properties; however, IFN- signaling activates IFN-sensitive
genes (ISGs) that encode the expression of antiviral proteins to
control HCV replication. IFN- signaling proceeds by endog-
enous IFN- binding to membrane-bound receptors, which
activate Janus kinases and then phosphorylate STAT-1 and -2.
Activated STAT-1 and STAT-2 form a complex with IFN-
regulated factor 9, which translocates from the cytosol to the
nucleus. Following translocation, phosphorylated STAT-1 at-
taches to specific regions of DNA to activate antiviral ISGs.
HCV hijacks the innate immune responses by suppressing
both upstream and downstream events of IFN signaling (12),
including decreased STAT-1 methylation (7, 10), thereby in-
terfering with ISG activation.
Ethanol also affects protein methylation by suppressing multi-
ple methylation reactions in the liver (18) and reducing IFN-
induced STAT-1 phosphorylation in hepatocytes and hepatoma
cells (28, 33). Furthermore, a study using CYP2E1 Huh7 cells
harboring HCV replicon clearly demonstrated that ethanol metab-
olism, but not ethanol itself, impaired IFN- signaling (16).
However, we do not know whether ethanol metabolism syner-
gizes with HCV to reduce STAT-1 methylation. In fact, this issue
has not been adequately addressed because most of the HCV-
ethanol in vitro studies were performed on the cell lines, which
either do not express the two main ethanol-metabolizing enzymes,
alcohol dehydrogenase (ADH) and cytochrome P4502E1
(CYP2E1), or express only CYP2E1. However, to use human
hepatocytes for HCV-ethanol studies as previously suggested (44)
is not the best option because hepatocytes in primary cultures
rapidly dedifferentiate and lose the expression of ethanol-metab-
olizing enzymes within 24 h, whereas in vitro infection of these
cells with HCV requires about 5 days, during which they lose the
expression of both ethanol-metabolizing enzymes (37). Thus
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hepatocytes cannot metabolize alcohol by the time they become
considerably infected. Here, we sought to mimic the effects of
ethanol metabolites, by exposing stably transfected CYP2E1
Huh7.5 cells to physiologically relevant levels of ethanol and to
acetaldehyde (Ach) that was continuously generated by an extra-
cellular Ach-generating system (AGS).
We hypothesized that, during HCV infection, ethanol me-
tabolites interfere with innate immunity by suppressing meth-
ylation of major IFN signal transduction factor, STAT-1,
thereby promoting liver injury. This hypothesis is based on our
previous findings that ethanol metabolism diminishes methyl-
transferase activities in the liver (18) and reduces IFN-
signaling, which is a key step in innate immunity induction in
HCV-infected liver cells. Here, we describe a pathogenic
insight into the role of both ethanol metabolism and HCV in
IFN-regulated activation of antiviral genes that control HCV
replication. We present evidence that the ethanol metabolite,
Ach, suppresses ISG activation attributable to protein phospha-
tase 2A (PP2A)-dependent impairment of STAT-1 methyl-
ation, which provides a temporal increase in HCV RNA and
sensitizes cells to Ach-induced apoptosis.
MATERIALS AND METHODS
Reagents and Media
High-glucose DMEM, Williams medium, and FBS were purchased
from Invitrogen (Carlsbad, CA). Human recombinant IFN- was from
MACS-Miltenyi Biotech (San Diego, CA). TransAM DNA-binding
ELISA kit was from Active Motive (Carlsbad, CA). Antibody to
phosphorylated STAT-1 (Tyr 701) was from Cell Signaling (Beverly,
MA); antibodies to the STAT-1, protein inhibitor of activated STAT-1
(PIAS-1), and -actin were from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-mono-dimethyl arginine and methylated lysine anti-
bodies were from Abcam (Cambridge, MA). PP2A, CYP2E1, and
pPP2A were from EMD Millipore (Temecula, CA) and LifeSpan
Biosciences (Seattle, WA), respectively. Anti-ADH was a gift from
Dr. Michael Felder (University of South Carolina). Reagents used for
RNA isolation, cDNA synthesis, and real-time PCR were from Life
Technologies (Carlsbad, CA). Other reagents, all of analytical grade
quality, were from Sigma (St. Louis, MO).
Animal Studies
C57Bl/6J mice transgenically expressing HCV structural proteins
obtained from Dr. S. Weinman (Kansas University Medical Center)
were characterized elsewhere (21, 30). Mice (6–8 wk old) were
divided into four groups (n  6 per group): control, ethanol, betaine,
and betaine  ethanol. They were pair fed control and ethanol Lieber
De Carli diets for 10 days, with or without 2% betaine (wt/vol); then
were gavaged with PBS/maltose dextran or ethanol on day 11 and
killed 9 h after gavaging, as described in detail for a chronic-acute
ethanol study (2). Four hours before death, each mouse was injected
intraperitoneally with mouse IFN- (1,000 IU). In this study, we
observed no differences in alcohol consumption between ethanol and
ethanol  betaine groups. There was no difference in liver weight
either between each group (control: 1.01  0.05 g; ethanol: 1.18 
0.06 g; betaine: 1.08  0.03 g; ethanol  betaine: 1.03  0.06 g) or
body weight among the four groups after feeding.
Mice were treated according to the criteria outlined in the Guide for
the Care and Use of Laboratory Animals. Animal use and protocols of
ethanol feeding were approved by the Institutional Animal Care and
Use Biosafety Committees at VA Medical Center, Omaha, NE.
To characterize the changes in protein methylation, S-adenosylmethio-
nine:S-adenosylhomocysteine (SAM:SAH) ratios were measured by high-
performance liquid chromatography in crude liver homogenates (19).
Betaine was used as a promethylating agent to correct impaired
protein methylation via the restoration of a normal SAM:SAH ratio.
Also, 2=-5=-oligoadenylate synthase-like protein (OASL) and ISG15
mRNAs (ISGs) were quantified in the liver tissue using RT-PCR.
Cells
Huh7.5 cells. Huh7.5 cells were transfected with pIV-G2
(CYP2E1) plasmid as previously described for other cell lines (6, 31)
using Lipo TAXI (Invitrogen). Recombinant cells, designated RLW
cells, were selected in culture medium containing G418 at 400 g/ml
(Fig. 1A). Clones were expanded and screened for CYP2E1 expres-
sion and activity. Because we were unable to transfect Huh7.5 cells
with the ADH plasmid, we used exogenously produced acetaldehyde
generated by a special in vitro system (AGS, see description below).
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Fig. 1. Effects of acetaldehyde-generating system (AGS) on RLW cells. A:
phenotype of RLW cells. Immunoblot (IB) analysis showing that RLW cells
lack alcohol dehydrogenase (ADH) but express CYP2E. Lane 1, molecular
weight markers; lane 2, lysate primary mouse hepatocytes as a positive control;
lanes 3–4, lysates of RLW cells. B: kinetics of acetaldehyde (Ach) production
by AGS after indicated times of exposure to RLW cells. C: lactate dehydro-
genase (LDH) activity in AGS- or ethanol (EtOH)-treated RLW cells. Cells
were exposed to AGS or 50 mM EtOH for 48 h (earlier time points showed no
cytotoxicity in preliminary experiments). Cells lysed by sonication were used
as a positive control (100% LDH leakage). Percent cytotoxicity was calculated
as a percentage of positive control in treated samples, means  SE. A–C show
representative data from 3 independent experiments with similar results.
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Human hepatocytes. Human hepatocytes were from Triangle Re-
search Laboratories (Research Triangle Park, NC) (2 batches, tripli-
cate readings).
Cell Treatments
RLW cells were infected by JFH1 (HCV genotype 2a) virus at a
multiplicity of infection (MOI) of 0.1 as previously described (40) or
were left uninfected. To investigate whether ethanol metabolites
affected IFN- signaling, on day 2 after infection, cells were exposed
for up to 48 h to AGS added directly to the culture medium. The AGS
included yeast ADH (0.02 U/ml), 2 mM nicotinamide adenine dinu-
cleotide and 50 mM ethanol (EtOH). One unit of ADH catalyzes the
reduction of M NADH formed per minute at 37°C. In the presence
of RLW cells, the levels of Ach measured by gas chromatography in
the medium fluctuate between about 250 (at 1–4 h of exposure) and
50 M (at 18–48 h of exposure) (Fig. 1B). These levels of Ach
correspond to the amount of Ach produced by ADH-expressing liver
cells (6, 33) and to the physiological concentrations observed in the
liver of ethanol consumers. At the end of treatments, cells were
stimulated with IFN- (time and dose depended on the end points of
the experiment, see RESULTS). Cytotoxicity was measured by lactate
dehydrogenase release to cell medium as described (6) (Fig. 1C). To
assess the involvement of impaired protein methylation in the regu-
lation of IFN- signaling, all treatments were done in the presence or
absence of 2 mM betaine, a promethylating agent. The optimal
concentration of betaine used for in vitro studies in liver cells was
determined earlier (20).
Human hepatocytes were attached to collagen-coated six-well
plates (4	 105 cells/well) and then infected via serum from an HCV
patient (IRB no. 520-14-EX; HCV RNA is 3 	 106 copies/ml), 50
l/well. Infected cells were cultured in Williams medium supple-
mented with antibiotics and 5% human serum of AB group for 3 days
and then exposed to either medium or 50 mM ethanol or to AGS for
48 h. After incubation, the cells were stimulated with human IFN-,
200 IU, for 4 h, and then lysed and processed for real-time PCR as
described below. HCV infection in hepatocytes was confirmed by
detection of HCV RNA.
RNA isolation and real-time PCR. ISGs with antiviral activities,
such as viperin, 2=-5=-oligoadenylate synthetase 1 (OAS1), protein
kinase R, OASL, and ISG15, were quantified by real-time PCR. Total
RNA was isolated from cells using Trizol reagent. A two-step proce-
dure was used, in which 200 ng RNA was reverse-transcribed to
cDNA using the high-capacity reverse transcription kit. In the second
step, the cDNA was amplified using TaqMan Universal Master Mix II
with fluorescent-labeled primers (TaqMan gene expression systems).
These were incubated in a Model 7500 qRT-PCR thermal cycler. The
relative quantity of each RNA transcript was calculated by its thresh-
old cycle (Ct) after subtracting that of the reference cDNA (GAPDH).
RNA was also isolated from mouse liver tissue, and ISGs were
quantified (using primer probes for mice) in the same way as specified
for human cells. Data are expressed as the quantity of transcript. The
relative HCV RNA expression level in infected cells was quantified
using the following primers and probe for this consensus sequence
designed with the help of PrimerExpress Software v. 2.0 (Applied
Biosystems, Foster City, CA): 5=UTRF GACCGGGTCCTTTCTTG-
GAT; 5=UTRR CCAACACTACTCGGCTAGCAGTCT; probe FAM-
ATTTGGGCGTGCCCCCGC-NFQ.
Immunoblotting and immunoprecipitation. Cell lysates were pre-
pared in 0.5 M EDTA, 2 M Tris, 20 mM Na3VO4, 200 mM Na4P2O7,
100 mM PMSF, 1 M NaF, 20% Triton X-100, and aprotinin, pH 7.
Nuclear fractions were collected using an Active Motif kit (Carlsbad,
CA). Immunoprecipitations were done by incubating each Ag-Ab com-
plex with protein G Sepharose (GE Healthcare Biosciences, Uppsala,
Sweden) overnight in a rotating shaker at 4°C, followed by washing and
incubation with SDS-PAGE sample-solubilizing buffer at 95°C for 10
min. Isotype-specific IgG was used as a negative control. Complexes
were subsequently subjected to denaturing SDS-PAGE in polyacryl-
amide gels. Immunoblotting was performed as described previously,
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Fig. 2. IFN-sensitive gene (ISG) activation in RLW cells exposed to AGS. Hepatitis C virus (HCV)-infected RLW cells were exposed to 50 mM ethanol or AGS
for 48 h in the presence or absence of betaine, and then cells were treated with 200 U of IFN- for 4 h. Treatment with this IFN dose for 4 h did not affect HCV
RNA levels in the cells (not shown). Real-time PCR analysis was performed for the expression of ISGs (mRNAs). A: 2=-5=-oligoadenylate synthetase 1 (OAS1).
B: 2=-5=-oligoadenylate synthase-like protein (OASL). C: viperin. D: protein kinase R (PKR). GAPDH was used to normalize the gene of interest. Data are
generated from 3 independent experiments and presented as means  SE. Bars with different letters are significantly different at P  0.05.
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blots were developed using Odyssey infrared imaging system, and the
protein band was quantified using Li-Cor software (39). -Actin was
used as the loading control to normalize the proteins.
HCV core and BODIPY staining. 50,000 cells/well were seeded onto
coverslips inserted in each well of a 24-well plate. Cells were infected
with JFH-1 virus (MOI  0.1). After overnight incubation of cells with
virus, virus-containing medium was removed and replenished with fresh
media. Cells were cultured for another 48 h. After 48 h of AGS treatment,
cells were washed with PBS, fixed with 4% paraformaldehyde for 15 min
at 37°C, permeabilized with 0.5% Triton X-100 for 5 min at room
temperature, and blocked for 30 min with 5% goat serum in PBS. Cells
were stained to study the colocalization of HCV core protein with the
lipid droplets. First, cells were incubated with antibody to HCV core
(clone: C7-50, dilution 1:300; catalog no. MA1-080; Thermo Scientific,
Rockford, IL) for 1 h. The cells were then washed and incubated with the
mixture of Alexa Fluor 594-labeled secondary antibody for HCV core
and BODIPY (to stain lipid droplets, 1:100) for another hour. Nuclei
were labeled with DAPI. The coverslips were transferred to microscope
slides for imaging by using a 	63 lens in a LSM 710 confocal micro-
scope (Carl Zeiss, Peabody, MA).
Statistical Analyses
Data from at least three independent experiments are expressed as
means  SE. Comparisons among multiple groups were determined
by one-way ANOVA, using a Tukey’s post hoc test. For comparisons
between the two groups, we used Student’s t-test. A probability value
of 0.05 or less was considered significant.
RESULTS
Ethanol Metabolism and ISG Activation in HCV-Infected
Liver Cells
RLW cells were infected with HCV and treated with AGS
(in the presence or absence of betaine) for 48 h, and then
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Fig. 3. Effects of EtOH or Ach on STAT-1 attachment to DNA and protein inhibitor of activated STAT-1 (PIAS-1)-STAT-1 complex. After exposure to medium,
50 mM ethanol, or AGS for 48 h in the presence or absence of betaine, cells were treated with 1,000 IU of IFN- for 30 min to measure pSTAT-1 attachment
to DNA in nuclear fractions by ELISA. Nontreated (with either AGS, ethanol, or IFN-) cells were used as a control. A: HCV cells. B: HCV cells. Values
from cells treated with IFN- only are expressed as 100%. Results are expressed as the percentage of DNA binding in IFN--stimulated cells and are means 
SE. Bars with different letters indicate significant differences at P  0.05. C: PIAS-1-STAT-1 complex formation in HCV and HCV cells. Immunoprecipi-
tation (IP), PIAS-1; IB, pSTAT-1. Lane 1, nontreated cells; lane 2, IFN-; lane 3, EtOH  IFN-; lane 4, EtOH  IFN-  betaine; lane 5, AGS  IFN-;
lane 6, AGS  IFN-  betaine, representative IP data. D and E: quantification of pSTAT-1. PIAS-1 ratio obtained in HCV and HCV cells, the results of
3 independent experiments, means  SE. Bars with different letters are significantly different at P  0.05.
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activation of antiviral ISGs was induced (for details, see figure
legends). As shown in Fig. 2, A–D, in CYP2E1 cells, only the
AGS, not ethanol alone, suppressed IFN--induced activation
of ISGs, indicating that Ach or the combination of Ach with
CYP2E1-generated ethanol metabolites (but not CYP2E1-gen-
erated ethanol metabolites in the absence of Ach) regulate this
downstream step of IFN- signaling. Subsequent betaine ex-
posure either fully or partially restored ISG expression.
Ethanol Metabolism and STAT-1 Attachment to DNA
ISG activation by IFN- depends on the binding of activated
(phosphorylated) STAT-1 to DNA. Here, STAT-1 attachment
to DNA was measured in nuclear extracts using a TransAM
DNA binding ELISA kit. In HCV RLW cells, ethanol expo-
sure alone suppressed DNA binding by only 13%, whereas the
AGS suppressed binding by 42% compared with untreated
IFN- controls (Fig. 3, A and B). The magnitude of this
reduction was comparable in both HCV and HCV RLW
cells. Betaine treatment partially (up to 69–75% of IFN-
control) restored Ach-impaired DNA binding of STAT-1.
Ethanol Metabolism and PIAS-1-STAT-1 Complex Formation
PIAS-1 competes with DNA for the binding to STAT-1.
Lysates from ethanol/AGS-treated HCV and HCV RLW
cells were immunoprecipitated with anti-PIAS-1 and then
probed for pSTAT-1 (Fig. 3, C–E). Only the combination of
CYP2E1 and Ach increased PIAS-1-pSTAT-1 complex forma-
tion by about twofold. This effect was even more prominent in
HCV than in noninfected cells (AGS IFN- vs. IFN-) and
was prevented by betaine treatment.
Ethanol Metabolism and STAT-1 Methylation
Cell lysates from treated HCV and HCV cells were
immunoprecipitated either with antibody to methyl arginine or
methyl lysine and then probed for STAT-1. Ach reduced
methylation of STAT-1 on both residues (Figs. 4, A–C, and 5,
A–C). The magnitude of Ach-induced reduction in STAT-1
methylation was higher in HCV-infected than in noninfected
cells (for methyl arginine, 50% vs. 27% and for methyl lysine,
62% vs. 38%, respectively), indicating that HCV synergizes
with Ach in suppressing protein methylation. The effect of
ethanol metabolites on STAT-1 methylation was reversed by
betaine treatment.
The decrease in protein methylation is attributed to sup-
pression of appropriate methyltransferase activities. The
specific inhibitors of protein arginine methyltransferase
(PRMT1), lysine methyltransferase and the pan-methylation
inhibitor, tubercidin, were next used to relate the suppres-
sion in STAT-1 methylation to the downstream step of
IFN- signaling, an impaired attachment of STAT-1 to
DNA (Fig. 5D). As shown, 50 M arginine methylation
inhibitor (AMI) (a PRMT1 inhibitor) reduced STAT-1 bind-
ing to DNA by 20%; 10 g/ml BIX (an inhibitor of histone
lysine methyltransferase) suppressed it by 30%, and tuber-
cidin reduced it by 60% of IFN--stimulated control, indi-
cating that DNA attachment of activated STAT-1 is regu-
lated by more than one methyltransferase. In addition, we
observed a dose-dependent decline by AMI on STAT-1
DNA binding (Fig. 5E), underscoring the importance of
arginine methylation for the regulation of STAT-1 attach-
ment to DNA and the downstream ISG activation.
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Fig. 4. Effects of Ach on arginine STAT-1 methylation. HCV and HCV RLW cells were treated as described above. IP, methyl arginine; IB, STAT-1. A:
HCV and HCV cells. Lane 1, control; lane 2, IFN-; lane 3, IFN-  betaine; lane 4, AGS  IFN-; lane 5, AGS  IFN-  betaine, shown as a
representative IP. B and C: quantification of IP data from 3 independent experiments, presented as means  SE. Bars with different letters are significantly
different at P  0.05.
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Mechanism of the Regulation of STAT-1 Methylation by
Alcohol Metabolism
It is known that STAT-1 arginine methylation is suppressed
by HCV through PP2A-dependent downregulation of PRMT1
activity (7). To date, the involvement of PP2A in the regulation
of methylation by Ach additive to HCV effect has not been
explored. To study whether PP2A regulates the impairment of
STAT-1 arginine methylation, RLW cells were treated with
AGS-generated Ach for 48 h in the presence or absence of the
PP2A inhibitor, okadaic acid (OA, 5 nM). Cell lysates were
immunoprecipitated with anti-methyl arginine and then probed
for STAT-1 by Western blot. Tubercidin treatment (2.5 M)
for 24 h served as a positive control for the reduction of
STAT-1 methylation. OA by itself did not affect STAT-1
methylation, but PP2A suppression was protected from the
reduction of STAT-1 methylation by Ach (Fig. 6A). Further-
more, OA treatment reversed an Ach-induced enhancement in
PIAS-1-STAT-1 complex formation (Fig. 6B), indicating that
PP2A has an impact on Ach-impaired STAT-1 methylation and
PIAS-1-STAT-1 complexion. To investigate whether Ach ac-
tivates PP2A, we measured the effect of Ach on total and
phosphorylated PP2Ac (pPP2Ac) subunit because phosphory-
lation decreases PP2A activity (14). The pPP2A/total PP2A
ratio after Ach treatment is presented in Fig. 6, C–F. pPP2/
PP2A ratio was lower in HCV-infected than in noninfected
cells and was further suppressed by Ach, indicating that PP2A
activity is induced by Ach and is higher in HCV-infected than
in noninfected cells. Activation of PP2A by Ach was prevented
by betaine treatment.
Effects of Ethanol/Ethanol Metabolism on HCV RNA
To study the impact of HCV- and ethanol metabolism-
induced changes in IFN signaling on HCV replication, we
measured the levels of HCV RNA in infected cells treated with
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AGS. Figure 7A shows that, in RLW cells, HCV RNA was
transiently increased threefold after 24 h of incubation with
AGS, but, after 48 h of AGS exposure, it declined to near
control levels. Similar kinetics of HCV core protein localized
to lipid droplets was observed in cells after AGS treatment
(Fig. 7B); the intensity of HCV core fluorescence per cell fell
from 3.8  2.5 in untreated cells to 0.448  0.448 in the cells
exposed for 48 h to AGS (P  0.01). This suggests that a
temporary rise followed by depletion of HCV RNA in HCV-
infected cells occurs in response to Ach. The decline in expression
of HCV core-positive cells and HCV RNA is likely related to
Ach-elicited induction of apoptosis in heavily infected cells after
24 h of AGS exposure. Hence, we measured cleaved caspase 3 as
the downstream parameters for apoptosis and found that the
amount of cleaved caspase 3 increased during exposure to Ach,
reaching a maximum after 48 h (Fig. 7, C and D).
As a proof of concept that suppression of ISG and persis-
tence of HCV RNA observed in hepatocyte-like hepatoma cells
resembles the effects of ethanol metabolism in primary liver
cells, we repeated the same AGS treatments in human hepato-
cytes. We found a similar reduction in expression of antiviral
ISGs after cell treatment with AGS as observed in Huh7.5
cells; this reduction was apparently methylation dependent
because it was attenuated by betaine (Fig. 8, A–D). As ex-
pected, ethanol exposure alone did not affect ISG levels be-
cause expression of ethanol-metabolizing enzymes in the hepa-
tocytes was extinguished. This was confirmed by the lack of
Ach present in the media of the ethanol-treated cells. Thus, in
human hepatocytes, AGS induced a numeric increase in HCV
RNA compared with IFN--treated samples (P 
 0.07), and
this increase was significantly reversed by betaine (P 
 0.02)
(Fig. 8E).
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To link the in vitro and in vivo effects of ethanol metabolism
on ISG activation, we measured OASL and ISG15 mRNAs in
HCV transgenic (Tg) mice given control and ethanol liquid
diets with or without betaine. Ethanol feeding significantly
(P 
 0.01) reduced ISGs, whereas inclusion of betaine in the
ethanol diet partially restored ISG expression (Fig. 9, A and B).
In addition, the SAM:SAH ratio (a hallmark of methylation
reactions) in livers of these animals was lower in ethanol-fed
than in control mice (Fig. 9C), indicating suppression of
methylation reactions in livers of HCV ethanol-fed mice,
which was restored by betaine cotreatment.
DISCUSSION
In this study, we addressed a clinically relevant mechanism
of methylation-related impairment in IFN- signaling triggered
by ethanol metabolism. By itself, IFN-, which is endoge-
nously produced by liver and immune cells, does not possess
antiviral properties. However, it activates signaling events in
the cells by inducing ISGs that encode synthesis of antiviral
proteins. Thus dysregulation of IFN signaling reduces protec-
tion from HCV, thereby allowing HCV infection progression
(24, 35). Although HCV-induced hijacking of innate immunity
has been extensively investigated (22, 36), the role of alcohol
and, especially, alcohol metabolism in potentiation of HCV-
induced defects of IFN signaling remains unclear.
Here, we explored the possibility that alcohol exposure to
liver cells promotes HCV-elicited dysregulation of IFN- sig-
naling via impairment of methylation reactions. We focused
our investigation on downstream events in IFN- signaling that
depend on STAT-1 methylation (26) and directly activate
ISGs. HCV infection reduces STAT-1 methylation via PP2A-
induced downregulation of PRMT1, which catalyzes methyl-
ation of STAT-1 on Arg 31 (7–9). This mechanism seems to be
quite universal for viral hepatitis because similar changes in
protein methylation were also observed in HBV infection (5).
However, previously it was not clear whether ethanol metab-
olites, particularly Ach, potentiate HCV-induced suppression
of IFN- signaling.
To examine the effects of ethanol metabolism on IFN-
signaling, we created hepatocyte-like conditions in HCV-in-
fected Huh7.5 cells by stable transfection with CYP2E1 plas-
mid and in vitro exposure to AGS that contains ADH to
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generate physiological levels of Ach. AGS induced little to no
toxic effects in Huh7.5 cells during 48-h treatment.
The present study revealed that only the combination of
CYP2E1-generated alcohol metabolites and AGS-generated
Ach efficiently suppressed activation of multiple antiviral ISGs
in HCV-infected RLW cells. We confirmed these findings by
similar experiments with human hepatocytes infected with
HCV, as well as by results of in vivo studies. To attribute
Ach-mediated ISG suppression to impaired protein methyl-
ation, AGS-exposed cells were treated with or without the
promethylating agent, betaine. Importantly, Huh7.5 cells are
responsive to betaine in restoration of methylation cycle be-
cause they express betaine-homocysteine S-methyltransferase.
In contrast to the traditional promethylating agent SAM, be-
taine does not lower hepatoma cell viability and thus is better
suited for in vitro studies on hepatoma cells.
Analyzing the events in IFN- signaling, which are up-
stream from ISG activation, we found that, in HCV RLW
cells, AGS suppressed the binding of phosphorylated STAT-1
to DNA. Ach likely plays a pivotal role in these effects
because, in CYP2E1-expressing cells, exposure to ethanol
alone did not suppress IFN- signaling. These changes (usu-
ally, more profound in HCV-infected RLW cells) were also
observed in HCV cells, indicating that, although Ach poten-
tiates the suppression of IFN- signaling by HCV, it also
decreases IFN--induced signal transduction in the absence of
HCV. In our hands, Ach-mediated reduction in STAT-1 at-
tachment to DNA was attenuated by betaine. Furthermore, a
decline of STAT-1 attachment to DNA by specific PRMT1 or
lysine methyltransferase inhibitors, as well as by the pan-
methylation inhibitor, tubercidin, supports the notion that there
is important methylation-dependent regulation of this signaling
step.
PIAS-1 is a negative regulator of IFN signaling that com-
plexes with activated STAT-1 and competes for its attachment
to DNA (38). Here, Ach enhanced complex formation between
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PIAS-1 and activated STAT-1. This latter event was blocked
by betaine treatment and thus is methylation dependent. Fur-
thermore, blocking of PP2A activity by the PP2A inhibitor,
OA, reversed the activating effects of Ach on PIAS-1-STAT-1,
indicating that the increase in PIAS-1-STAT-1 complex for-
mation by Ach is controlled by PP2A. As demonstrated earlier,
HCV uses the PP2A mechanism to deactivate PRMT1, which
methylates STAT-1 on Arg 31 (7, 15). Our results indicated
that Ach potentiated HCV-induced impairment in STAT-1
methylation via PP2A by enhancing PP2A activity (by block-
ing PP2Ac phosphorylation to inactivate the enzyme). Further-
more, we found that Ach, in addition to suppressing STAT-1
arginine methylation (as HCV does), also blocks lysine meth-
ylation. Even if we observed a modest suppression of STAT-1
methylation by Ach, these changes seemed to be enough to
increase PIAS-1-STAT-1 complex formation, which, in turn,
prevented STAT-1 attachment to DNA and subsequent ISG
activation. The mechanism, by which Ach interferes with
IFN--induced activation of antiviral genes in HCV-infected
cells can be summarized as follows: suppression of STAT-1
methylation by HCV can be further exacerbated by Ach be-
cause of its ability to activate PP2Ac by downregulating PP2A
phosphorylation (Fig. 10A). The results of in vivo studies on
HCV Tg mice confirmed that chronic ethanol feeding, not
only suppressed protein methylation in the liver by lowering
the SAM:SAH ratio, but also inhibited IFN--induced ISG
activation. The ethanol-elicited reduction in ISG expression
was prevented (fully or partially) by inclusion of betaine in the
liquid diet.
Ethanol metabolism-induced changes in IFN signaling and
subsequent activation of antiviral ISGs suggest that HCV RNA
levels should go up in the cells with reduced innate immunity.
However, more detailed in vitro studies on HCV-infected
ethanol-metabolizing cells have shown that HCV RNA
amounts were gradually increased up to 24 h of AGS treatment
but, surprisingly, declined at 48 h almost back to pretreatment
levels. Moreover, after 48 h, we observed no infectivity in cell
supernatants (not shown), and the amount of HCV core protein
associated with lipid droplets was also decreased compared
with that after 24 h of incubation, indicating that infectious
HCV particles did not leak from infected cells, nor were they
harbored inside the cells. More importantly, HCV RNA and the
intracellular amount of HCV core protein were not absolutely
cleared up by Ach but just decreased after 48 h, indicating low
viral replication. Our explanation of these events is that long-
term persistence of HCV in liver cells is possible when a low
level of HCV persistence in hepatocytes is controlled by lipid
peroxidation, without interfering with cell viability (43). Fur-
thermore, in our earlier study on HCV-infected scid Alb-uPA
mice with humanized livers, in vivo ethanol feeding prolonged
the persistence of HCV RNA compared with the same mice on
control diet, without significant elevation of HCV RNA levels
(32), mimicking a scenario of an ethanol-induced switch from
acute to chronic HCV infection.
We believe that Ach, on one hand, induced temporal accu-
mulation of HCV in the cells and, on the other hand, triggered
proapoptotic effects, leading to induction of apoptotic cell
death in heavily infected RLW cells clearly seen after 48 h of
AGS treatment. Indeed, the levels of cleaved caspase 3 (ter-
minal caspase) were highest after 48 h of Ach exposure to
HCV Huh7-CYP (RLW) cells.
It is known that cell-to-cell communication in HCV-infected
liver can be established via exosomes (3, 23) or apoptotic
bodies (13). Apoptotic bodies may be captured by Kupffer and
stellate cells, thereby promoting inflammation and fibrosis
development (25, 27, 42). In addition, HCV proteins, including
core, NS3 and NS5 induce fibrogenic effects on hepatic stellate
cells (1, 41). Figure 10B summarizes a proposed pathogenic
mechanism of Ach-induced progression of HCV-induced hep-
atitis, which is now under investigation in our laboratory.
On the basis of the results of this study, suppression of
IFN- signaling by HCV and Ach reduces protection of cells
from the virus and enhances cell death by apoptosis. All of
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these events are at least partially dependent on impaired protein
methylation. Thus betaine should be included in the therapy
regimen for HCV-infected alcoholic patients undergoing treat-
ment with IFN type 1 and/or direct antiviral agents (DAA).
Indeed, a promising protective effect of the promethylating
agent, SAM, has been demonstrated in patients with HCV
treated with recombinant IFN- (11) in the absence of alcohol.
However, whereas, in patients with nonalcoholic HCV, the
combination of betaine with DAA is optional, we firmly
believe that it becomes “a must” in HCV alcohol abusers and
will substantially increase the effectiveness of DAA therapy in
this category of patients. Activation of the immune system
should follow antiviral effects of DAA to avoid a risk of
reinfection, as this possibility exists after DAA treatment (4).
In addition, betaine has been shown to reverse apoptosis of
hepatocytes in alcohol-fed rodents (19, 29). Therefore, it, not
only restores antiviral protection by ISG activation, but also
prevents apoptotic body formation, which appears to be a
pathogenic mechanism for ethanol metabolism-induced liver
injury progression in HCV infection.
We conclude that Ach generated from ethanol metabolism
enhances HCV-induced suppression of STAT-1 methylation,
thereby reducing attachment of activated STAT-1 to DNA
attributable to the PP2A-regulated increase in PIAS-1-STAT-1
complex formation. This ultimately results in blocked activa-
tion of ISGs. Enhanced replication of HCV sensitizes liver
cells to the proapoptotic effects of ethanol metabolism. All the
aforementioned negative events are based on impaired IFN
signaling, are methylation dependent, and can be fully or
partially reversed by betaine treatment.
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